Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MDR-Mtb SCAID 187.0 drug resistance reversion

ABSTRACT: Genomic insight into mechanisms of reversion of antibiotic resistance in multidrug resistant Mycobacterium tuberculosis induced by the nanomolecular iodine-containing complex FS-1

PROVIDER: PRJEB14806 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR1544440_1.fastq.gz	Fastqsanger.gz
	ERR1544440_2.fastq.gz	Fastqsanger.gz
	ERR1544431_1.fastq.gz	Fastqsanger.gz
	ERR1544431_2.fastq.gz	Fastqsanger.gz
	ERR1544441_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 22

Similar Datasets

RNA sequencing (RNA-Seq) of multi-drug resistant (MDR) cancer cells and MDR persister cancer cells.

Project description:To gain insight into the alterations of gene expression profile in the course of non-mutationally acquired resistance, we performed RNA-seq comparing MDR persister cells to MDR cancer cells.

2021-11-04 | GSE187441 | GEO

Reversion of Alzheimer’s disease signatures

Project description:Reversion of Alzheimer’s disease signatures

| PRJNA564801 | ENA

Macrophage responses to MDR M.tuberculosis infection

Project description:The emergence of multidrug resistant (MDR) Mycobacterium tuberculosis (Mtb) strains, resistant to the frontline anti-tubercular drugs rifampicin and isoniazid, forces treatment with less effective and toxic second-line drugs and stands to derail TB control efforts. However, the immune response to MDR Mtb infection remains poorly understood. Here, we determined the RNA transcriptional profile of in vitro generated macrophages to infection with either drug susceptible Mtb HN878 or MDR Mtb W_7642 infection.

2018-12-26 | GSE115495 | GEO

Acinetobacter baumannii MDR-ZJ06

Project description:Multidrug resistant isolate

| PRJNA28333 | ENA

MDR Enterobacteria

Project description:COLISTIN RESISTANCE IN MULTIDRUG-RESISTANT ENTEROBACTERIACEAE IN CAMBODIA

| PRJNA1107516 | ENA

In vitro activation and reversion of human primary hepatic stellate cells

Project description:Liver fibrosis is characterized by the excessive formation and accumulation of matrix proteins as a result of wound healing in the liver. A main event during fibrogenesis is the activation of the liver resident quiescent hepatic stellate cell (qHSC). Recent studies suggest that reversion of the activated HSC (aHSC) phenotype into a quiescent-like phenotype could be a major cellular mechanism underlying fibrosis regression in the liver, thereby offering new therapeutic perspectives for the treatment of liver fibrosis. The goal of the present study is to identify experimental conditions that can revert the activated status of human HSCs and to map the molecular events associated with this phenotype reversion by gene expression profiling Transcriptomic profiling of primary human quiescent HSCs (qHSCs), in vitro activated HSCs (aHSCs) and in vitro reverted HSCs (rHSCs). The cell types come from different donors (This is detailed in the original manuscript.).

2015-08-12 | E-GEOD-68001 | biostudies-arrayexpress

MDR Salmonella enterica

Project description:Multidrug resistant strains of different Salmonella enterica serotypes

| PRJEB52018 | ENA

In vitro activation and reversion of human primary hepatic stellate cells

2015-08-12 | GSE68001 | GEO

Control of Cellular Differentiation Trajectories for Cancer Reversion

Project description:Control of Cellular Differentiation Trajectories for Cancer Reversion

| PRJNA1449984 | ENA

PolyA RNA-seq from Human esophageal biopsy samples from eosinophilic esophagitis patients

Project description:Analysis of steady-state mRNA levels in 27 samples from healthy controls and patients with fibrostenotic EoE and non-fibrostenotic EoE. Participants range 5 – 18 years old. EoE participants had >15 eosinophils per hpf (eos/hpf) and were classified as fibrostenotic (FS) or non-fibrostenotic (non-fs). FS EoE: having either a) a stricture and/or b) grade 2 or 3 concentric esophageal rings and an esophageal distensibility < 15 mm. Non-fs EoE: no clinical evidence for stricture, circumferential rings or history of food impaction. Included control subjects had no identified abnormalities on endoscopy or histology. Results provide insight into the pathways involved in fibrostenotic remodeling in EoE.

2023-04-08 | GSE197702 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data